Showing results (501-510 of 688) with videos related to

Sort By:
Pageof 69
Journal of Visualized Experiments : Jove|October 22, 2016
Nutrient Regulation by Continuous Feeding for Large-scale Expansion of Mammalian Cells in SpheroidsBradley P Weegman, Ahmad Essawy, Peter Nash, et al.
Australasian Journal on Ageing|September 24, 2020
Education, occupation and operational measures of sarcopenia: Six years of Australian dataSharon L Brennan-Olsen, Sara Vogrin, Saliu Balogun, et al.
BMJ Open Sport & Exercise Medicine|October 11, 2021
Clinical relevance of MRI knee abnormalities in Australian rules football players: a longitudinal studyDawn Aitken, Saliu Balogun, Yi Chao Foong, et al.
JAMA Network Open|April 8, 2025
Yoga or Strengthening Exercise for Knee Osteoarthritis: A Randomized Clinical TrialBedru J Abafita, Ambrish Singh, Dawn Aitken, et al.
Rheumatology (Oxford, England)|January 13, 2024
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysisPhilip J Mease, Dafna D Gladman, Joseph F Merola, et al.
Journal of Colloid and Interface Science|January 17, 2025
Protecting monoclonal antibodies via competitive interfacial adsorption of nonionic surfactantsZeyuan Zhuang, Haoran Wu, Zongyi Li, et al.
ACS Omega|October 14, 2024
Thin Film TaFe, TaCo, and TaNi as Potential Optical Hydrogen Sensing MaterialsLars J Bannenberg, Isa M Veeneman, Folkert I B Straus, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2014
Combined hydrogels that switch human pluripotent stem cells from self-renewal to differentiationJames E Dixon, Disheet A Shah, Catherine Rogers, et al.
Rheumatology and Therapy|July 3, 2023
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBruce W Kirkham, Alexander Egeberg, Frank Behrens, et al.
Seminars in Arthritis and Rheumatism|December 8, 2022
Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studiesEmilce E Schneeberger, Gustavo Citera, Peter Nash, et al.
Pageof 69